WHAT IS CLAIMED IS:

1. ~~A method of treating a disorder associated with altered vascular barrier function in a subject comprising administering to the subject~~Use of a RASIP1 modulator in the manufacture of a medicament for treating a disorder associated with altered vascular barrier function in a subject.

2. The use~~method~~ of claim 1, wherein the disorder is associated with reduced vascular barrier function and wherein the RASIP1 modulator is a RASIP1 agonist.

3. The use~~method~~ of claim 2, wherein the disorder is selected from the group consisting of sepsis, age-related macular degeneration (AMD), edema, ischemic stroke and hemorrhage.

4. The use~~method~~ of claim 1, wherein the disorder is associated with increased vascular barrier function and wherein the RASIP1 modulator is a RASIP1 antagonist.

5. The use~~method~~ of claim 4, wherein the disorder is hypertension.

6. The use~~method~~ of any of claims 1-5, wherein the RASIP1 modulator is a small molecule.

7. ~~A method of reducing or inhibiting vascular barrier function in a subject in need thereof, comprising administering to the subject~~Use of a RASIP1 agonist in the manufacture of a medicament for reducing or inhibiting vascular barrier function in a subject in need thereof.

8. ~~A method of increasing or enhancing vascular barrier function in a subject in need thereof, comprising administering to the subject~~Use of a RASIP1 antagonist in the manufacture of a medicament for increasing or enhancing vascular barrier function in a subject in need thereof.

9. ~~A method of treating a disorder that requires new vessel formation in a subject comprising administering to the subject~~Use of a RASIP1 inhibitor in the manufacture of a medicament for treating a disorder that requires new vessel formation in a subject.

10. The use~~method~~ of claim 9, wherein the disorder is cancer or a proliferative retinopathy.